Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Status:
Completed
Trial end date:
2017-01-18
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if bortezomib can help to control MDS.
The safety of this drug will also be studied.
Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer
cells to die.